Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Malignant canine mammary epithelial cells shed exosomes containing differentially expressed microRNA that regulate oncogenic networks

Authors: Eric J. Fish, Kristopher J. Irizarry, Patricia DeInnocentes, Connor J. Ellis, Nripesh Prasad, Anthony G. Moss, R. Curt Bird

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Breast (mammary) cancers in human (BC) and canine (CMT) patients share clinical, pathological, and molecular similarities that suggest dogs may be a useful translational model. Many cancers, including BC, shed exosomes that contain microRNAs (miRs) into the microenvironment and circulation, and these may represent biomarkers of metastasis and tumor phenotype.

Methods

Three normal canine mammary epithelial cell (CMEC) cultures and 5 CMT cell lines were grown in serum-free media. Exosomes were isolated from culture media by ultracentrifugation then profiled by transmission electron microscopy, dynamic light scattering, and Western blot. Exosomal small RNA was deep-sequenced on an Illumina HiSeq2500 sequencer and validated by qRT-PCR. In silico bioinformatic analysis was carried out to determine microRNA gene and pathway targets.

Results

CMEC and CMT cell lines shed round, “cup-shaped” exosomes approximately 150–200 nm, and were immunopositive for exosomal marker CD9. Deep-sequencing averaged ~ 15 million reads/sample. Three hundred thirty-eight unique miRs were detected, with 145 having > ±1.5-fold difference between one or more CMT and CMEC samples. Gene ontology analysis revealed that the upregulated miRs in this exosomal population regulate a number of relevant oncogenic networks. Several miRNAs including miR-18a, miR-19a and miR-181a were predicted in silico to target the canine estrogen receptor (ESR1α).

Conclusions

CMEC and CMT cells shed exosomes in vitro that contain differentially expressed miRs. CMT exosomal RNA expresses a limited number of miRs that are up-regulated relative to CMEC, and these are predicted to target biologically relevant hormone receptors and oncogenic pathways. These results may inform future studies of circulating exosomes and the utility of miRs as biomarkers of breast cancer in women and dogs.
Appendix
Available only for authorised users
Literature
1.
Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, Capurro C, et al. Cancer incidence in pet dogs: findings of the animal tumor registry of Genoa, Italy. J Vet Intern Med. 2008;22:976–84.CrossRefPubMed
2.
Sorenmo KU, Worley DR, Goldschmidt MH. Ch. 27: tumors of the mammary gland. In: Withrow SJ, Vail DM, Page RL, editors. Withrow & MacEwen’s small animal clinical oncology. 5th ed. St. Louis: Saunders Elsevier; 2013. p. 538–56.CrossRef
3.
Rasotto R, Berlato D, Goldschmidt MH, Zappulli V. Prognostic significance of canine mammary tumor histologic subtypes: an observational cohort study of 229 cases. Veterinary Pathol. 2017;54(4):571–8.CrossRef
4.
Egenvall A, Bonnett BN, Ohagen P, Olson P, Hedhammar A, von Euler H. Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002. Prev Vet Med. 2005;69:109–27.CrossRefPubMed
5.
Perez Alenza MD, Peña L, del Castillo N, Nieto AI. Factors influencing the incidence and prognosis of canine mammary tumours. J Small Anim Pract. 2000;41(7):287–91.CrossRefPubMed
6.
Lim HY, Im KS, Kim NH, Kim HW, Shin JI, Yhee JY, et al. Effects of obesity and obesity-related molecules on canine mammary gland tumors. Vet Pathol. 2015;52(6):1045–51.CrossRefPubMed
7.
Pinho SS, Carvalho S, Cabral J, Reis CA, Gärtner F. Canine tumors: a spontaneous animal model of human carcinogenesis. Transl Res. 2012;159(3):165–72.CrossRefPubMed
8.
Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, Castle J, et al. Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics. 2009;10:135.CrossRefPubMedPubMedCentral
9.
Lutful Kabir FM, DeInnocentes P, Bird RC. Altered microRNA expression profiles and regulation of INK4A/CDKN2A tumor suppressor genes in canine breast cancer models. J Cell Biochem. 2015;116(12):2956–69.CrossRefPubMed
10.
Shinoda H, Legare ME, Mason GL, Berkbigler JL, Afzali MF, Flint AF, et al. Significance of ERα, HER2, and CAV1 expression and molecular subtype classification to canine mammary gland tumor. J Vet Diagn Investig. 2014;26(3):390–403.CrossRef
11.
Lutful Kabir FM, DeInnocentes P, Agarwal P, Mill CP, Riese DJ, Bird RC. Estrogen receptor-α, progesterone receptor, and c-erbB/HER-family receptor mRNA detection and phenotype analysis in spontaneous canine models of breast cancer. J Vet Sci. 2017;18(2):149–58.CrossRef
12.
Chang CC, Tsai MH, Liao JW, Chan JP, Wong ML, Chang SC. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors. J Am Vet Med Assoc. 2009;235(4):391–6.CrossRefPubMed
13.
Simon D, Schoenrock D, Nolte I, Baumgartner W, Barron R, Mischke R. Cytologic examination of fine-needle aspirates from mammary gland tumors in the dog: diagnostic accuracy with comparison to histopathology and association with postoperative outcome. Vet Clin Pathol. 2009;38(4):521–8.CrossRefPubMed
14.
Cassali GD, Gobbi H, Malm C, Schmitt FC. Evaluation of accuracy of fine needle aspiration cytology for diagnosis of canine mammary tumours: comparative features with human tumours. Cytopathology. 2007;18(3):191–6.PubMed
15.
Chang SC, Chang CC, Chang TJ, Wong ML. Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998–2002). J Am Vet Med Assoc. 2005;227(10):1625–9.CrossRefPubMed
16.
Philibert JC, Snyder PW, Glickman N, Glickman LT, Knapp DW, Waters DJ. Influence of host factors on survival in dogs with malignant mammary gland tumors. J Vet Intern Med. 2003;17(1):102–6.CrossRefPubMed
17.
18.
Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics: a comprehensive review. EMBO Mol Med. 2012;4(3):143–59.CrossRefPubMedPubMedCentral
19.
Suzuki H, Maruyama R, Yamamoto E, Kai M. Epigenetic alteration and microRNA dysregulation in cancer. Front Genet. 2013;4(258):1–8.
20.
Antolín S, Calvo L, Blanco-Calvo M, Santiago MP, Lorenzo-Patiño MJ, Haz-Conde M, et al. Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer. 2015;15:297.CrossRefPubMedPubMedCentral
21.
Li Q, Liu M, Ma F, Luo Y, Cai R, Wang L, et al. Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS ONE. 2014;9(8):e104870.CrossRefPubMedPubMedCentral
22.
Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, Burda P, et al. Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer. 2014;14:448.CrossRefPubMedPubMedCentral
23.
Wu Q, Guo L, Jiang F, Li L, Li Z, Chen F. Analysis of the miRNA–mRNA–lncRNA networks in ER+ and ER- breast cancer cell lines. J Cell Mol Med. 2015;19(12):2874–87.CrossRefPubMedPubMedCentral
24.
Boggs RM, Wright ZM, Stickney MJ, Porter WW, Murphy KE. MicroRNA expression in canine mammary cancer. Mamm Genome. 2008;19(7–8):561–9.CrossRefPubMed
25.
Osaki T, Sunden Y, Sugiyama A, Azuma K, Murahata Y, Tsuka T, et al. Establishment of a canine mammary gland tumor cell line and characterization of its miRNA expression. J Vet Sci. 2016;17(3):385–90.CrossRefPubMedPubMedCentral
26.
27.
Bulkowska M, Rybicka A, Senses KM, Ulewicz K, Witt K, Szymanska J, et al. MicroRNA expression patterns in canine mammary cancer show significant differences between metastatic and non-metastatic tumours. BMC Cancer. 2017;17(1):728.CrossRefPubMedPubMedCentral
28.
Heishima K, Ichikawa Y, Yoshida K, Iwasaki R, Sakai H, Nakagawa T, et al. Circulating microRNA-214 and -126 as potential biomarkers for canine neoplastic disease. Sci Rep. 2017;7(1):2301.CrossRefPubMedPubMedCentral
29.
Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110(1):13–21.CrossRefPubMed
30.
Penfornis P, Vallabhaneni KC, Whitt J, Pochampally R. Extracellular vesicles as carriers of microRNA, proteins and lipids in tumor microenvironment. Int J Cancer. 2016;138(1):14–21.CrossRefPubMed
31.
He WA, Calore F, Londhe P, Canella A, Guttridge DC, Croce CM. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci U S A. 2013;111(12):4525–9.CrossRef
32.
Thery C, Clayton A, Amigorena S, et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;3.22.1–3.22.29.
33.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8.CrossRefPubMed
34.
Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43(D1):46–52.CrossRef
35.
Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):P3.CrossRefPubMed
36.
37.
38.
Yang VK, Loughran KA, Meola DM, Juhr CM, Thane KE, Davis AM, et al. Circulating exosome microRNA associated with heart failure secondary to myxomatous mitral valve disease in a naturally occurring canine model. J Extracell Vesicles. 2017;6(1):1350088.
39.
Charrin S, Jouannet S, Boucheix C, Rubinstein E. Tetraspanins at a glance. J Cell Sci. 2014;127:3641–8.CrossRefPubMed
40.
Lutful Kabir FM. Altered expression profiles and defects in a group of cell cycle regulators and tumor suppressor genes (INK4) and evaluation of comprehensive expression profiles of canine miRNAs in spontaneous canine breast cancer models. PhD dissertation: Auburn University; 2014. https://​etd.​auburn.​edu/​handle/​10415/​4429. Accessed 6 Dec 2017
41.
Raposo-Ferreira TMM, Brisson BK, Durham AC, Laufer-Amorim R, Kristiansen V, Puré E, et al. Characteristics of the epithelial-mesenchymal transition in primary and paired metastatic canine mammary carcinomas. Vet Pathol. 2018; https://​doi.​org/​10.​1177/​0300985818776054​. [Epub ahead of print]
42.
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–66.CrossRefPubMed
43.
44.
Fish E, DeInnocentes P, Prasad N, Moss A, Bird R. Normal and malignant canine mammary epithelial cells shed exosomes in vitro with differentially expressed microRNA profiles by deep-sequencing analysis [abstract]. In: Abstracts from ESVONC/ECVP Joint Meeting, Nantes 2016. Nantes: Vet Comp Oncol; 2016. 11 May 2017 https://​doi.​org/​10.​1111/​vco.​12313.
Metadata
Title
Malignant canine mammary epithelial cells shed exosomes containing differentially expressed microRNA that regulate oncogenic networks
Authors
Eric J. Fish
Kristopher J. Irizarry
Patricia DeInnocentes
Connor J. Ellis
Nripesh Prasad
Anthony G. Moss
R. Curt Bird
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4750-6

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Lack of association between cigarette smoking and Epstein Barr virus reactivation in the nasopharynx in people with elevated EBV IgA antibody titres

Research article

The DNA methylation profile of liver tumors in C3H mice and identification of differentially methylated regions involved in the regulation of tumorigenic genes

Review

Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy

Research article

MYC amplification in subtypes of breast cancers in African American women

Research article

Obesity and breast cancer outcomes in chemotherapy patients in New Zealand – a population-based cohort study

Database

PDXliver: a database of liver cancer patient derived xenograft mouse models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits